|Daily Range||$31.18 - $33.33|
|52-Week Range||$13.15 - $34.65|
|Dividend (Yield)||$0.00 (0.0%)|
|Average Daily Volume||260,755|
|Current FY EPS||-$3.56|
PTC Therapeutics, Inc. (PTCT) Description
PTC Therapeutics, Inc. Website: http://www.ptcbio.com/
Sarepta Therapeutics fell on its 144-week data, but the approvability -- based on trials run by PTC Therapeutics and Prosensa -- is likely to be based on 48-week data.
Sarepta Therapeutics is down over 20% today on disappointing clinical trial news. Here's what you need to know.
PTC Therapeutics Initiates Confirmatory Phase 3 Clinical Trial of Translarna™ (ataluren) in Patients With Nonsense Mutation Cystic Fibrosis (nmCF)
Despite the FDA recently providing a regulatory pathway for Sarepta's Duchenne muscular dystrophy drug, the stock is still one of the most heavily shorted in health care. Here's why.
PTC shares soar after receiving positive comments from Credit Suisse. However, here's what shareholders should really be focused on.